These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1102 related articles for article (PubMed ID: 32009785)

  • 1. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.
    Chen F; Liu Q; Xiong Y; Xu L
    Int J Nanomedicine; 2021; 16():4225-4237. PubMed ID: 34188471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.
    Youshia J; Lamprecht A
    Expert Opin Drug Deliv; 2016; 13(2):281-94. PubMed ID: 26637060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances.
    Hu S; Zhao R; Xu Y; Gu Z; Zhu B; Hu J
    J Mater Chem B; 2023 Dec; 12(1):13-38. PubMed ID: 38018424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients.
    Schmidt C; Lautenschlaeger C; Collnot EM; Schumann M; Bojarski C; Schulzke JD; Lehr CM; Stallmach A
    J Control Release; 2013 Jan; 165(2):139-45. PubMed ID: 23127508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hierarchical structured and programmed vehicles deliver drugs locally to inflamed sites of intestine.
    Li W; Li Y; Liu Z; Kerdsakundee N; Zhang M; Zhang F; Liu X; Bauleth-Ramos T; Lian W; Mäkilä E; Kemell M; Ding Y; Sarmento B; Wiwattanapatapee R; Salonen J; Zhang H; Hirvonen JT; Liu D; Deng X; Santos HA
    Biomaterials; 2018 Dec; 185():322-332. PubMed ID: 30267958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.
    Zhang S; Ermann J; Succi MD; Zhou A; Hamilton MJ; Cao B; Korzenik JR; Glickman JN; Vemula PK; Glimcher LH; Traverso G; Langer R; Karp JM
    Sci Transl Med; 2015 Aug; 7(300):300ra128. PubMed ID: 26268315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
    Zhang Y; Thanou M; Vllasaliu D
    Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine-mediated drug delivery for potential treatment of inflammatory bowel disease: a narrative review.
    Ardekani ZM; Lorenzo-Leal AL; Bach H
    Nanomedicine (Lond); 2024 Jan; 19(2):163-179. PubMed ID: 38284393
    [No Abstract]   [Full Text] [Related]  

  • 11. Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease.
    Li X; Lu C; Yang Y; Yu C; Rao Y
    Biomed Pharmacother; 2020 Sep; 129():110486. PubMed ID: 32768972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease.
    Yang C; Sharma K; Mow RJ; Bolay E; Srinivasan A; Merlin D
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101333. PubMed ID: 38490294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug delivery strategies in the therapy of inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Fischer D; Stallmach A
    Adv Drug Deliv Rev; 2014 May; 71():58-76. PubMed ID: 24157534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological features-based targeted delivery strategies in IBD therapy: A mini review.
    Li S; Zhang F; Zhang Q
    Biomed Pharmacother; 2022 Jul; 151():113079. PubMed ID: 35605297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
    Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
    Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges.
    Nunes R; Neves JD; Sarmento B
    Nanomedicine (Lond); 2019 Oct; 14(19):2631-2644. PubMed ID: 31612773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease.
    Li DF; Yang MF; Xu HM; Zhu MZ; Zhang Y; Tian CM; Nie YQ; Wang JY; Liang YJ; Yao J; Wang LS
    J Mater Chem B; 2022 Aug; 10(31):5853-5872. PubMed ID: 35876136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease.
    Li S; Xie A; Li H; Zou X; Zhang Q
    J Control Release; 2019 Dec; 316():66-78. PubMed ID: 31682913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Saccharomyces boulardii as a treatment option in IBD.
    Sivananthan K; Petersen AM
    Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):465-475. PubMed ID: 29771163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current pharmaceutical strategies for efficient site specific delivery in inflamed distal intestinal mucosa.
    Sharma S; Sinha VR
    J Control Release; 2018 Feb; 272():97-106. PubMed ID: 29317245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.